XSHE
300896
Market cap4.30bUSD
Oct 09, Last price
95.03CNY
1D
-0.16%
1Q
6.24%
IPO
-50.01%
Name
Imeik Technology Development Co Ltd
Chart & performance
P/E
22.27
P/S
11.86
EPS
4.27
Div yield, %
5.25%
Shrs. gr., 5y
-0.09%
Rev. gr., 5y
10.85%
Revenues
2.42b
-19.89%
Net income
1.29b
-34.05%
CFO
1.39b
-28.04%
Dividend
Sep 03, 20261 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Imeik Technology Development Co.,Ltd. specializes in the research, development, manufacturing, and distribution of biomedical materials. The company's diverse product portfolio caters to both the medical aesthetics field and general skincare needs. Within its medical beauty offerings, Imeik provides a range of recognized brands including Moisten Angel, IFRESH, Yimei, Hearty, Bonita Bonita, and Tightly. Additionally, its comprehensive skincare line features hydrating lotions, anti-aging and firming serums, concentrated essence creams, revitalizing facial masks, restorative chitosan B5 sprays, and clarifying and illuminating liquids. Established in 2004, the company's operations are based in Beijing, China.
Key people
Jun Jian
Chairman of the Board · since 2016
Renchao Zhang
Finance Director (Chief Financial Officer), Staff Elected Director · since 2025
Yifeng Shi
General Manager, Director · since 2016
Yonglei Yin
Deputy General Manager · since 2016
Lina Gou
Deputy General Manager, Chief Sales Officer · since 2016
Dongmei Li
Deputy General Manager, Secretary of the Board · since 2025
Qing Jian
Director · since 2025
Xinyang Lin
Director · since 2016
Independent Director · since 2025
Gang Chen
Independent Director · since 2022
Yuqun Yu
Independent Director · since 2022
Daqi Zhu
Independent Director · since 2022
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||